Elkins is basically the number 2 of the company. Not sure that this is the right approach.
As ex Celgene holders we were accustomed to being the partner of choice for small and emerging biotech companies in a period were funding for these companies was readily available.
Now most biotech companies are cash starved and yet BMY is not a partner of choice for these cash desperate companies.
This is where we should focus our criticism. At least that’s what i wrote to them in my personal name (never got an acknowledgment).
BMY needs a multitude of XLRN type of deals.